Triomics has developed an AI-based platform to enhance cancer care by helping trial operators secure patients for clinical trials, prevent delays in patient care, eliminate backlogs and inefficiencies, and eliminate provider burnout. The company’s work revolves around the development of an AI model named OncoLLM, trained specifically to analyze unstructured oncology data, greatly reducing time wasted on manual data analysis while improving accuracy in patient-trial matching. OncoLLM’s primary function is to speed up the process of matching cancer patients with suitable clinical trials by reading and processing data from their medical records.
Key customers and partnerships
In May 2024, the company noted that its solution was being used by six cancer centers and hospitals, a number it plans to double by the end of the year.
Triomics partners with academic cancer centers and researchers to develop generative AI benchmarks, safety protocols, and other best practices. Its partners include the Collaboration for Oncology-focused LLM Training and the Cancer Informatics for Cancer Centers Society.
Funding and financials
In May 2024, the company raised USD 15 million in a venture funding round, which saw participation from investors including Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator. The raised funds were set aside to develop the company’s platform and roll it out to new customers.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.